TransCardiac Therapeutics

TransCardiac Therapeutics was a medical technology company focused on developing innovative systems for the local delivery of therapeutic agents to the heart. The company's core technology was a transpericardial delivery system that allowed for the minimally invasive administration of drugs, genes, and cells directly into the pericardial space. This localized approach was designed to treat cardiovascular conditions such as heart failure, atrial fibrillation, and myocardial ischemia while reducing the risks associated with systemic drug delivery. Founded in 2001 based on research from the National Institutes of Health (NIH), the company aimed to bridge the gap between advanced biologics and effective cardiac administration. In 2004, TransCardiac Therapeutics was acquired by Medtronic, which integrated the delivery technology into its broader cardiovascular portfolio.